(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.14%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally...
Stats | |
---|---|
本日の出来高 | 33 842.00 |
平均出来高 | 113 079 |
時価総額 | 27.92B |
EPS | $0.598 ( 2023-06-30 ) |
次の収益日 | ( $0.0800 ) 2024-05-09 |
Last Dividend | $0.0740 ( 2023-05-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | 38.93 |
ATR14 | $0.0390 (0.31%) |
ボリューム 相関
Coloplast A/S 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Coloplast A/S 相関 - 通貨/商品
Coloplast A/S 財務諸表
Annual | 2023 |
収益: | $24.50B |
総利益: | $16.33B (66.64 %) |
EPS: | $22.21 |
FY | 2023 |
収益: | $24.50B |
総利益: | $16.33B (66.64 %) |
EPS: | $22.21 |
FY | 2022 |
収益: | $22.58B |
総利益: | $15.53B (68.78 %) |
EPS: | $22.15 |
FY | 2021 |
収益: | $19.43B |
総利益: | $13.31B (68.53 %) |
EPS: | $2.27 |
Financial Reports:
No articles found.
Coloplast A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.210 (N/A) |
$0 (N/A) |
$0.0740 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0810 | 2021-05-14 |
Last Dividend | $0.0740 | 2023-05-19 |
Next Dividend | $0 | N/A |
Payout Date | 2023-05-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $0.649 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.55 | -- |
Div. Sustainability Score | 6.57 | |
Div.Growth Potential Score | 3.44 | |
Div. Directional Score | 5.00 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SOUHY | Ex Dividend Junior | 2023-09-14 | Annually | 0 | 0.00% | |
HFBA | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
ANSLY | Ex Dividend Knight | 2023-08-23 | Semi-Annually | 0 | 0.00% | |
NSARO | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
CYFL | Ex Dividend Knight | 2023-09-05 | Quarterly | 0 | 0.00% | |
THYCF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
IGGHY | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
BDULF | Ex Dividend Knight | 2023-09-12 | Annually | 0 | 0.00% | |
PPWLM | Ex Dividend Junior | 2023-07-19 | Quarterly | 0 | 0.00% | |
EKTAY | Ex Dividend Knight | 2023-08-25 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.195 | 1.500 | 6.11 | 9.16 | [0 - 0.5] |
returnOnAssetsTTM | 0.100 | 1.200 | 6.66 | 7.99 | [0 - 0.3] |
returnOnEquityTTM | 0.424 | 1.500 | 6.40 | 9.60 | [0.1 - 1] |
payoutRatioTTM | 0.957 | -1.000 | 0.433 | -0.433 | [0 - 1] |
currentRatioTTM | 0.532 | 0.800 | -2.34 | -1.871 | [1 - 3] |
quickRatioTTM | 0.324 | 0.800 | -2.80 | -2.24 | [0.8 - 2.5] |
cashRatioTTM | 0.0484 | 1.500 | -0.842 | -1.263 | [0.2 - 2] |
debtRatioTTM | 0.445 | -1.500 | 2.58 | -3.87 | [0 - 0.6] |
interestCoverageTTM | 9.31 | 1.000 | 7.66 | 7.66 | [3 - 30] |
operatingCashFlowPerShareTTM | 25.30 | 2.00 | 1.568 | 3.14 | [0 - 30] |
freeCashFlowPerShareTTM | 19.61 | 2.00 | 0.195 | 0.389 | [0 - 20] |
debtEquityRatioTTM | 1.430 | -1.500 | 4.28 | -6.42 | [0 - 2.5] |
grossProfitMarginTTM | 0.667 | 1.000 | 2.21 | 2.21 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.273 | 1.000 | 6.53 | 6.53 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.256 | 1.000 | 9.69 | 9.69 | [0.2 - 2] |
assetTurnoverTTM | 0.515 | 0.800 | 9.90 | 7.92 | [0.5 - 2] |
Total Score | 6.57 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.90 | 1.000 | 9.71 | 0 | [1 - 100] |
returnOnEquityTTM | 0.424 | 2.50 | 7.69 | 9.60 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 19.61 | 2.00 | 3.46 | 0.389 | [0 - 30] |
dividendYielPercentageTTM | 0.353 | 1.500 | 1.165 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 25.30 | 2.00 | 1.568 | 3.14 | [0 - 30] |
payoutRatioTTM | 0.957 | 1.500 | 0.433 | -0.433 | [0 - 1] |
pegRatioTTM | 0.0290 | 1.500 | -3.14 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.221 | 1.000 | 6.97 | 0 | [0.1 - 0.5] |
Total Score | 3.44 |
Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。